Novel Naturally Occurring Dipeptides and Single-Stranded Oligonucleotide Act as Entry Inhibitors and Exhibit a Strong Synergistic Anti-HIV-1 Profile
Open Access
- 7 April 2022
- journal article
- research article
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 11 (3) , 1103-1116
Abstract
Introduction The availability of new classes of antiretroviral drugs is critical for treatment-experienced patients due to drug resistance to and unwanted side effects from current drugs. Our aim was therefore to evaluate the anti-HIV-1 activity of a new set of antivirals, dipeptides (WG-am or VQ-am) combined with a single-stranded oligonucleotide (ssON). The dipeptides were identified as naturally occurring and enriched in feces and systemic circulation in HIV-1-infected elite controllers and were proposed to act as entry inhibitors by binding to HIV-1 gp120. The ssON is DNA 35-mer, stabilized by phosphorothioate modifications, which acts on the endocytic step by binding to cell host receptors and inhibiting viruses through interference with binding to nucleolin. Methods Chou–Talalay’s Combination Index method for quantifying synergism was used to evaluate the drug combinations. Patient-derived chimeric viruses encoding the gp120 (env region) were produced by transient transfection and used to evaluate the antiviral profile of the combinations by drug susceptibility assays. Results We found that the combination WG-am:ssON or VQ-am:ssON had low combination index values, suggesting strong antiviral synergism. Of the two combinations, WG-am:ssON (1 mM:1 μM) had high efficacy against all prototype or patient-derived HIV-1 isolates tested, independent of subtype including the HIV-1-A6 sub-subtype. In addition, the antiviral effect was independent of co-receptor usage in patient-derived strains. Conclusion WG-am and ssON alone significantly inhibited HIV-1 replication regardless of viral subtype and co-receptor usage, and the combination WG-am:ssON (1 mM:1 μM) was even more effective due to synergism.Keywords
Funding Information
- Svenska Forskningsrådet Formas (521-2014-6718, 2016-01675, 2020-02129)
- Stockholms Läns Landsting (FoUI-955284, FoUI-953887)
This publication has 37 references indexed in Scilit:
- Emerging Antiviral Strategies to Interfere with Influenza Virus EntryMedicinal Research Reviews, 2013
- A Novel Enzyme-Linked Immunosorbent Assay for Screening HIV-1 Fusion Inhibitors Targeting HIV-1 Gp41 Core StructureSLAS Discovery, 2011
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay MethodCancer Research, 2010
- Identification of a Possible Ancestor of the Subtype A1 HIV Type 1 Variant Circulating in the Former Soviet UnionAIDS Research and Human Retroviruses, 2008
- TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-βNature Immunology, 2008
- Potential antivirals and antiviral strategies against SARS coronavirus infectionsExpert Review of Anti-infective Therapy, 2006
- The Calculated Genetic Barrier for Antiretroviral Drug Resistance Substitutions Is Largely Similar for Different HIV-1 SubtypesJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 ActivityAntimicrobial Agents and Chemotherapy, 2005
- Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteinsProceedings of the National Academy of Sciences, 2004
- Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitorsAdvances in Enzyme Regulation, 1984